Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin for Low-Risk SBP in Cirrhosis
NCT04437810Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jul 2020
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in spontaneous bacterial peritonitis (SBP) comparing Albumin + SMT with Placebo + SMT (2 arms). Primary endpoint: Proportion of patients having development / progression of Acute Kidney Injury at Day 7. Status: unknown.
02
Drugs
albumin (human)
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT04437810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04437810.